Minirin (Desmopressin)

Desmopressin, the active ingredient in Minirin, is a vasopressin (antidiuretic hormone) analog presented as a sublingual tablet for sublingual use. It is indicated for the management of central diabetes insipidus, primary nocturnal enuresis in children, and as a hemostatic agent to raise factor VIII and von Willebrand factor levels in patients with hemophilia A or von Willebrand disease.

GNH USA supplies Minirin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide.

Desmopressin acts on the antidiuretic hormone pathway to regulate water balance and coagulation. - Central diabetes insipidus: reduces excessive urine output by increasing renal water reabsorption. - Primary nocturnal enuresis: decreases nighttime bedwetting episodes in children by concentrating urine. - Hemophilia A and von Willebrand disease (as a hemostatic agent): elevates plasma factor VIII and von Willebrand factor levels to improve clot formation.

Desmopressin may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Nasal congestion or dryness: due to sublingual administration. - Nausea or abdominal discomfort. - Hyponatraemia: mild reduction in serum sodium. - Flushing or warmth sensation.

Serious or Rare Side Effects: - Severe hyponatraemia with seizures or coma. - Water intoxication leading to cerebral oedema. - Allergic reactions: rash, itching, or angioedema. - Thrombotic events: rare clot formation in predisposed patients.

When prescribing Desmopressin, clinicians should consider several safety and handling precautions. - Assess fluid balance: monitor intake and output to avoid water overload. - Check serum sodium: baseline and periodic measurement, especially in at‑risk patients. - Use caution in renal impairment: adjust monitoring as reduced clearance may increase risk. - Avoid concurrent use of other antidiuretic agents: such as carbamazepine or tricyclic antidepressants. - Contraindicated in uncontrolled hyponatraemia: do not initiate therapy. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Desmopressin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with other antidiuretic agents (e.g., carbamazepine, tricyclic antidepressants): may precipitate severe hyponatraemia. - NSAIDs (e.g., ibuprofen, naproxen): can reduce renal prostaglandin synthesis and increase risk of water retention.

Moderate Interactions (Monitor Closely): - Diuretics (especially thiazides): may exacerbate electrolyte disturbances. - Anticoagulants (e.g., warfarin): enhanced haemostatic effect may affect clotting parameters. - CYP‑mediated drugs: although desmopressin is not extensively metabolised, monitor for unexpected effects.